Loading
A phase 2 trial of Relmacabtagene autoleucel, Fludarabine, Cyclophosphamide in follicular lymphoma, run by Shanghai Ming Ju Biotechnology Co., Ltd., active and no longer recruiting.
Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL is a phase 2 interventional study registered as NCT06093841 by Shanghai Ming Ju Biotechnology Co., Ltd., with 46 participants planned, started 2023-11-03 and due to reach its primary completion in 2024-01-21. Interventions recorded: Relmacabtagene Autoleucel, Fludarabine, Cyclophosphamide. Conditions listed: Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma, Mediastinal B-Cell Diffuse Large Cell Lymphoma. No results are recorded here; the registry entry is the source.
Shares Relmacabtagene autoleucel, JW Therapeutics, CAR-T cell therapy.
Shares Fludarabine, Follicular lymphoma, Cyclophosphamide, CAR-T cell therapy.
Shares Relmacabtagene autoleucel, JW Therapeutics, CAR-T cell therapy.
Shares Fludarabine, Follicular lymphoma, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide, CAR-T cell therapy.
Shares Fludarabine, Cyclophosphamide, CAR-T cell therapy.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.